Bidirectional modification of a Galbulimima alkaloid identifies selective opioid ligands

05 June 2025, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

We report a bidirectional diversification and optimization campaign of the newly identified mu- and kappa-opioid receptor antagonist GB18, a naturally occurring Galbulimima alkaloid. First, we find that replacement of the GB18 piperidine with pyridine alters the pharmacology from antagonism to partial agonism, with reduced potency but markedly higher receptor selectivity for kappa- over mu-. Second, we optimize this hit via development of a mutually chemoselective cross-coupling of an alkyl iodide/ vinyl triflate pair that leads to a series of low- and sub-nanomolar KOR-selective full agonists, some of which demonstrate bias for G protein activation over βarrestin2 recruitment. Third, we advance three leads to in vivo (mouse) analysis and demonstrate brain penetrance and behavioral effects. In an open-field activity assay, we demonstrate that by increasing G protein signaling preference, agonists display an increase in exploratory, anxiolytic-like behaviors with no signs of sedation. The brevity and success of this campaign, combined with in vitro and in vivo pharmacology, demonstrate GB18 and its analogs as tractable new opioid scaffolds that allow favorable properties to be dialed in and unwanted properties removed.

Keywords

opioids
kappa
total synthesis
cross-coupling
anxiolytic

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
All data are made available in the main text or the Supporting Information, including experimental procedures, copies of NMR spectra, X-ray structure reports, full outlines of prior syntheses and all pharmacological protocols. Structural parameters for X-ray crystal structures are available from the Cambridge Crystallographic Data Centre ((–)-4: CCDC 2168687; (+)-4: CCDC 2168686; (+)-2: CCDC 2171738; RS1122: CCDC 2248063).
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.